Mga Batayang Estadistika
| CIK | 1569340 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Cell Source, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-55413 CELL SOURCE, INC. (Exact name of registrant as specified in its c |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Cell Source, Inc. (Exact name of registrant as specified in its charter) Nevada 000-55413 32-0379665 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| June 27, 2025 |
Exhibit 16.1 June 27, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Cell Source, Inc. under Item 4.01 of its Form 8-K dated June 26, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Cell Source, Inc. contained therein. V |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-55413 CUSIP NUMBER 15114L104 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2 |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. ( |
|
| November 14, 2024 |
EXHIBIT 10.73 STOCK PURCHASE AGREEMENT This Stock Purchase Agreement (the “Agreement”) is made as of this 20th day of August, 2024 by and among Cell Source, Inc., a Delaware corporation (the “Company”), and David Zolty Investment ULC, a Canadian Unlimited Liability Corporation, Solomon Zolty Investment ULC, a Canadian Unlimited Liability Corporation, Honey Kamenetsky Investment ULC, a Canadian Unl |
|
| August 19, 2024 |
Exhibit 10.71 AMENDMENT No. 3 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT This Amendment No. 3 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and entered into as of May 1, 2023 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson”), a member institution of The University of |
|
| August 19, 2024 |
EXHIBIT 10.70 AMENDMENT No. 2 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT This Amendment No. 2 to the Veto Cell Production and Clinical Trial Program Agreement (“Amendment”) is made and entered into as of August 7, 2019 by and between Cell Source Limited (“Cell Source”) and The University of Texas M.D. Anderson Cancer Center (“MD Anderson”), a member institution of The University |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. (Exact |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-55413 CUSIP NUMBER 15114L104 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2024 |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. (Exac |
|
| June 24, 2024 |
Original Issue Discount Note issued to Helen Samuels Investment ULC Exhibit 10.74 CELL SOURCE, INC. ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE Original Issue Date: May 22, 2024 Subscription Amount: $31,250 Maturity Date: November 22, 2024, subject to mandatory prepayments Original Issue Discount: $6,250 Original Principal Amount: $37,500 FOR VALUE RECEIVED, Cell Source, Inc., a Nevada corporation (the “Company” or the “Company”), hereby promises to pay to the order o |
|
| June 24, 2024 |
Original Issue Discount Note issued to Honey Kamenetsky Investment ULC Exhibit 10.73 CELL SOURCE, INC. ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE Original Issue Date: May 22, 2024 Subscription Amount: $31,250 Maturity Date: November 22, 2024, subject to mandatory prepayments Original Issue Discount: $6,250 Original Principal Amount: $37,500 FOR VALUE RECEIVED, Cell Source, Inc., a Nevada corporation (the “Company” or the “Company”), hereby promises to pay to the order o |
|
| June 24, 2024 |
Original Issue Discount Note issued to Darlene Soave Revocable Trust Exhibit 10.69 CELL SOURCE, INC. ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE Original Issue Date: May 22, 2024 Subscription Amount: $250,000 Maturity Date: November 22, 2024, subject to mandatory prepayments Original Issue Discount: $50,000 Original Principal Amount: $300,000 FOR VALUE RECEIVED, Cell Source, Inc., a Nevada corporation (the “Company” or the “Company”), hereby promises to pay to the orde |
|
| June 24, 2024 |
Original Issue Discount Note issued to David Zolty Investment ULC Exhibit 10.70 CELL SOURCE, INC. ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE Original Issue Date: May 22, 2024 Subscription Amount: $31,250 Maturity Date: November 22, 2024, subject to mandatory prepayments Original Issue Discount: $6,250 Original Principal Amount: $37,500 FOR VALUE RECEIVED, Cell Source, Inc., a Nevada corporation (the “Company” or the “Company”), hereby promises to pay to the order o |
|
| June 24, 2024 |
Original Issue Discount Note issued to Solomon Zolty Investment ULC Exhibit 10.71 CELL SOURCE, INC. ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE Original Issue Date: May 22, 2024 Subscription Amount: $31,250 Maturity Date: November 22, 2024, subject to mandatory prepayments Original Issue Discount: $6,250 Original Principal Amount: $37,500 FOR VALUE RECEIVED, Cell Source, Inc., a Nevada corporation (the “Company” or the “Company”), hereby promises to pay to the order o |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55413 Cell Source, Inc. (Exact name of reg |
|
| June 24, 2024 |
Original Issue Discount Note issued to Phyllis Friedman Investment ULC Exhibit 10.72 CELL SOURCE, INC. ORIGINAL ISSUE DISCOUNT PROMISSORY NOTE Original Issue Date: May 22, 2024 Subscription Amount: $125,000 Maturity Date: November 22, 2024, subject to mandatory prepayments Original Issue Discount: $25,000 Original Principal Amount: $150,000 FOR VALUE RECEIVED, Cell Source, Inc., a Nevada corporation (the “Company” or the “Company”), hereby promises to pay to the orde |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 Cell Source, Inc. (Exact name of registrant as specified in its charter) Nevada 001-55413 32-0379665 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-55413 CUSIP NUMBER 15114L104 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2 |
|
| November 9, 2023 |
Exhibit 10.39(d) |
|
| November 9, 2023 |
Amendment No. 2 to 10% Convertible Note Exhibit 10.68(b) |
|
| November 9, 2023 |
Certificate of Designation with respect to Series B Preferred Stock dated October 30, 2023. Exhibit 3.6 |
|
| November 9, 2023 |
Amendment No. 4 to Third Amended and Restated Note Exhibit 10.64(d) |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. ( |
|
| November 9, 2023 |
Exhibit 10.39(c) |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. (Exact |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. (Exac |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-55413 CUSIP NUMBER 15114L104 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: June 30, 2023 |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55413 Cell Source, Inc. (Exact name of reg |
|
| August 8, 2023 |
Amendment No. 1 to Third Amended and Restated Note Exhibit 10.64(a) Amendment No. 1 to Third Amended and Restated 10% Convertible Note This Amendment No. 1 to Third Amended and Restated 10% Convertible Note effective June 18, 2021 between Cell Source, Inc. (the “Company”) and Darlene Soave (the “Lender”) is effective as of this 31st day of December 2021 except as otherwise provided below; WHEREAS, the Company has previously issued to the Lender an |
|
| August 8, 2023 |
Amendment to Certificate of Designation with respect to Series C Preferred Stock Exhibit 3.6(a) |
|
| August 8, 2023 |
Amendment No. 1 to 10% Convertible Note Exhibit 10.68(a) Amendment No. 1 to 10% Convertible Note This Amendment No. 1 to 10% Convertible Note effective March 10, 2022 between Cell Source, Inc. (the “Company”) and George Verstraete (the “Lender”) is effective as of this 10th day of March 2023. WHEREAS, the Company has previously issued to the Lender a 10% Convertible Note (the “Note”) in the principal amount of up to $6,000,000 dated and |
|
| August 8, 2023 |
Amendment No. 2 to Third Amended and Restated Note Exhibit 10.64(b) Amendment No. 2 to Third Amended and Restated 10% Convertible Note This Amendment No. 2 to Third Amended and Restated 10% Convertible Note effective June 18, 2021 between Cell Source, Inc. (the “Company”) and Darlene Soave (the “Lender”) is effective as of this 28th day of October 2022. WHEREAS, the Company has previously issued to the Lender an 8% Convertible Note effective Octob |
|
| August 8, 2023 |
Amendment to Certificate of Designation with respect to Series A Preferred Stock Exhibit 3.5(a) |
|
| August 8, 2023 |
Amendment No. 3 to Third Amended and Restated Note EXHIBIT 10.64(c) Amendment No. 3 to Third Amended and Restated 10% Convertible Note This Amendment No. 3 to Third Amended and Restated 10% Convertible Note effective June 18, 2021 between Cell Source, Inc. (the “Company”) and Darlene Soave (the “Lender”) is effective as of this 28th day of April 2023. WHEREAS, the Company has previously issued to the Lender an 8% Convertible Note effective October |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-55413 CUSIP NUMBER 15114L104 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2023 |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-55413 CUSIP NUMBER 15114L104 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: December 31, 2 |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. ( |
|
| December 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. (Exact |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. (Exac |
|
| July 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2022 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55413 32-0379665 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| May 12, 2022 |
NT 10-Q 1 formnt10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-55413 CUSIP NUMBER 15114L104 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Per |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6. 2022 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-554134 32-0379665 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 15, 2022 |
Exhibit 4.1 DESCRIPTION OF COMMON STOCK The following is a brief description of shares of common stock (?common stock?) of Cell Source, Inc. (the ?Company,? ?we,? ?us,? or ?our?). The brief description is based upon our Articles of Incorporation, our Bylaws (our ?Bylaws?), and provisions of applicable Nevada law. This summary does not purport to be complete and is subject to, and qualified in its |
|
| April 15, 2022 |
10% Convertible Note issued to George Verstraete. EXHIBIT 10.68 NEITHER THIS Note nor the securities into which this note is convertible haVE been registered under the securities act of 1933, as amended (the ?act?), or under any state securities law AND NEITHER THIS NOTE NOR ANY INTEREST THEREIN NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE may be offered, sold, transferred, pledged or otherwise DISPOSED OF EXCEPT PURSUANT TO an effectiv |
|
| April 15, 2022 |
EXHIBIT 10.36(a) FIFTH AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this ?Amendment?) Effective Date: June 30th, 2019 By and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, ?Yeda?) and CELL SOURCE LIMITED a company duly registered under the laws of Israel of 5 Kineret Street, Bnei Brak 51262 |
|
| April 15, 2022 |
EXHIBIT 10.39(b) AMENDMENT No. 2 TO SPONSORED RESEARCH AGREEMENT This Amendment No. 2 to the Sponsored Research Agreement (?Amendment?) is made and entered into as of October 18, 2021 by and between Cell Source Limited (?Cell Source?) and The University of Texas M.D. Anderson Cancer Center (?MD Anderson?), a member institution of The University of Texas System (?System?). RECITALS A. Cell Source a |
|
| April 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55413 Cell Source, Inc. (Exact name of reg |
|
| April 15, 2022 |
EXHIBIT 10.63(a) EIGHTH AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this ?Amendment?) Effective Date: December 2, 2021 by and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 7610002, Israel (hereinafter, ?Yeda?) and CELL SOURCE LIMITED a company duly registered under the laws of Israel of 5 Kineret Street, Bnei Brak 5 |
|
| March 31, 2022 |
NT 10-K 1 formnt10-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: March 31, 2022 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-55413 CUSIP NUMBER 15114L104 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Per |
|
| March 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10. 2022 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-554134 32-0379665 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 15, 2021 |
Exhibit 10.39(b) |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. ( |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. (Exact |
|
| August 12, 2021 |
Third Amended and Restated Convertible Note issued to Darlene Soave. Exhibit 10.64 NEITHER THIS Note nor the securities into which this note is convertible haVE been registered under the securities act of 1933, as amended (the ?act?), or under any state securities law AND NEITHER THIS NOTE NOR ANY INTEREST THEREIN NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE may be offered, sold, transferred, pledged or otherwise DISPOSED OF EXCEPT PURSUANT TO an effectiv |
|
| August 12, 2021 |
Certificate of Designation with respect to Series C Preferred Stock dated July 27, 2021 Exhibit 3.6 |
|
| June 10, 2021 |
Option Agreement for 600,000 shares of Common Stock. EXHIBIT 1 CELL SOURCE, INC. (the ?Corporation?) 2019 ISRAELI EQUITY INCENTIVE SUB PLAN TO THE 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Cell Source, Inc. 2019 Equity Incentive Plan, including the 2019 Israeli Equity Incentive Sub-Plan (together hereinafter the ?Plan?) shall have the same defined meanings in this Stock Option Agreeme |
|
| June 10, 2021 |
Option Agreement for 750,000 shares of Common Stock. EX-2 3 ex2.htm EXHIBIT 2 CELL SOURCE, INC. (the “Corporation”) 2019 ISRAELI EQUITY INCENTIVE SUB PLAN TO THE 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Cell Source, Inc. 2019 Equity Incentive Plan, including the 2019 Israeli Equity Incentive Sub-Plan (together hereinafter the “Plan”) shall have the same defined meanings in this Stock |
|
| June 10, 2021 |
CLCS / Cell Source, Inc. / SHIMRAT ITAMAR Activist Investment SC 13D 1 formsc-13d.htm OMB APPROVAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response 14.5 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* CELL SOURCE, INC. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 15114L104 (CUS |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. ( |
|
| April 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SC 13D 1 clcssc13d.htm SC-13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response.......... 14.5 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* CELL SOURCE, INC. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities |
|
| April 21, 2021 |
Form of Warrant issued to the Reporting Person. EXHIBIT 1 WARRANT NO. Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT? |
|
| April 21, 2021 |
Amended and Restated Convertible Promissory Note issued by the Issuer to the Reporting Person. EXHIBIT 2 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), OR UNDER ANY STATE SECURITIES LAW AND NEITHER THIS NOTE NOR ANY INTEREST THEREIN NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS WHICH, IN THE OPINION OF COUNSEL SATISFACTORY TO THE COMPANY, IS AVAILABLE. |
|
| April 15, 2021 |
EXHIBIT 10.63 SEVENTH AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this ?Amendment?) Effective Date: November 15, 2020 by and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, ?Yeda?) and CELL SOURCE LIMITED a company duly registered under the laws of Israel of 5 Kineret Street, Bnei Brak 5126 |
|
| April 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55413 Cell Source, Inc. (Exact name of reg |
|
| April 15, 2021 |
EXHIBIT 10.60 NOTE EXCHANGE AGREEMENT THIS NOTE EXCHANGE AGREEMENT (this ?Agreement?) dated as of February 4, 2021 and effective as January 28, 2021, is made by and among CELL SOURCE, INC., a Nevada corporation, having its principal place of business at 57 West 57th Street, Suite 400, New York, New York 10019 (the ?Company?) and , a Delaware limited liability company maintaining business address a |
|
| April 15, 2021 |
Second Amended and Restated 10.0% Convertible Note. EX-10.62 4 clcsex1062.htm EX-10.62 EXHIBIT 10.62 WARRANT NO. Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF |
|
| April 15, 2021 |
Second Amended and Restated 10.0% Convertible Note. EXHIBIT 10.61 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW AND NEITHER THIS NOTE NOR ANY INTEREST THEREIN NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIV |
|
| April 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2021 Cell Source, Inc. (Exact name of registrant as specified in its charter) Nevada 001-55413 32-0379665 (State or other jurisdiction of incorporation) (Commission File Num |
|
| April 2, 2021 |
Darlene Soave Joins Cell Source’s Board of Directors EXHIBIT 99.1 Darlene Soave Joins Cell Source’s Board of Directors April 01, 2021 – New York, NY – Cell Source, Inc. (OTC: CLCS) (“Cell Source” or “the Company”), is the world leader in Veto Cell based innovative immunotherapy and today announced that Darlene Soave has been appointed to the Company’s Board of Directors, effective March 25, 2021. Veto Cells, in different mouse models, have shown tha |
|
| March 31, 2021 |
NT 10-K 1 clcsnt10k.htm NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING OMB APPROVAL OMB Number: 3235-0058 Expires: February 28, 2022 Estimated average burden hours per response 2.50 SEC FILE NUMBER 000-55413 CUSIP NUMBER 15114L104 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-C |
|
| December 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CELL SOURCE, INC. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 15114 21 04 (CUSIP Number) August 13, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| November 17, 2020 |
CLCS / Cell Source, Inc. / Yeda Research & Development Co., Ltd. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 CELL SOURCE, INC. (Name of Issuer) Common Stock, $.001 par value per share (1) (Title of Class of Securities) 15114 21 04 (CUSIP Number) November 1, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| November 13, 2020 |
Form of Warrant issued to Members of Scientific Advisory Board. EXHIBIT 10.54 WARRANT NO. CLCS ADV Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SE |
|
| November 13, 2020 |
Form of 8% Convertible Promissory Note. EX-10.58 6 clcsex1058.htm EX-10.58 EXHIBIT 10.58 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW AND NEITHER THIS NOTE NOR ANY INTEREST THEREIN NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSE |
|
| November 13, 2020 |
Form of Director Stock Option Agreement. EX-10.56 4 clcsex1056.htm EX-10.56 EXHIBIT 10.56 CELL SOURCE, INC. 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Cell Source, Inc. 2019 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (this “Option Agreement” or “Agreement”). Name: Address: The undersigned Participant has been grant |
|
| November 13, 2020 |
Form of Warrant issued to Service Providers. EX-10.55 3 clcsex1055.htm EX-10.55 EXHIBIT 10.55 WARRANT NO. CLCS ADV 200,000 Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE |
|
| November 13, 2020 |
Form of Warrant issued to Purchasers of 8% Convertible Promissory Note EXHIBIT 10.59 WARRANT NO. Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES |
|
| November 13, 2020 |
Form of Consultant Stock Option Agreement. EX-10.57 5 clcsex1057.htm EX-10.57 EXHIBIT 10.57 CELL SOURCE, INC. (the “Corporation”) 2019 ISRAELI EQUITY INCENTIVE SUB PLAN TO THE 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Cell Source, Inc. 2019 Equity Incentive Plan, including the 2019 Israeli Equity Incentive Sub-Plan (together hereinafter the “Plan”) shall have the same define |
|
| November 13, 2020 |
10-Q 1 clcs10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| August 14, 2020 |
Form of 10% OID Convertible Promissory Note. EXHIBIT 10.52 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGI |
|
| August 14, 2020 |
EXHIBIT 10.51 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 29, 2020, between Cell Source, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions set fo |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 Cell Source, Inc. (Exact |
|
| August 14, 2020 |
Form of Warrant issued to purchaser of 10% OID Convertible Promissory Note. EXHIBIT 10.53 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS |
|
| May 15, 2020 |
10-Q 1 clcs10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-5 |
|
| May 15, 2020 |
Form of Placement Agent Warrant dated February 13, 2020 EX-10.50 3 clcsex1050.htm EX-10.50 EXHIBIT 10.50 WARRANT NO. CLCS ADV Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITI |
|
| May 15, 2020 |
Convertible Promissory Note dated January 10, 2020 EXHIBIT 10.49 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE |
|
| March 30, 2020 |
EXHIBIT 10.48 Certain information has been excluded from this exhibit because (i) it is not material and (ii) would be competitively harmful if publicly disclosed. SIXTH AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this “Amendment”) Effective Date: December 31, 2019 By and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovo |
|
| March 30, 2020 |
CLCS / Cell Source, Inc. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55413 Cell Source, Inc. (Exact name of reg |
|
| March 30, 2020 |
Convertible Note effective October 28, 2019 EX-10.47 2 clcsex1047.htm EX-10.47 EXHIBIT 10.47 NEITHER THIS NOTE NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY STATE SECURITIES LAW AND NEITHER THIS NOTE NOR ANY INTEREST THEREIN NOR THE SECURITIES INTO WHICH THIS NOTE IS CONVERTIBLE MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSE |
|
| November 14, 2019 |
CLCS / Cell Source, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOU |
|
| August 14, 2019 |
Promissory Note dated July 29, 2019 Exhibit 10.55 |
|
| August 14, 2019 |
Convertible Promissory Note dated May 20, 2019 Exhibit 10.44 |
|
| August 14, 2019 |
Convertible Promissory Note dated July 2, 2019 EX-10.43 5 ex10-43.htm Exhibit 10.43 |
|
| August 14, 2019 |
CLCS / Cell Source, Inc. 10-Q - Quarterly Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOURCE, |
|
| August 14, 2019 |
Stock Option Agreement dated as of August 11, 2019 between Cell Source, Inc. and Yair Reisner Exhibit 10.42 CELL SOURCE, INC. 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Cell Source, Inc. 2019 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (this “Option Agreement” or "Agreement"). Name: Yair Reisner Address: The undersigned Participant has been granted an Option to purcha |
|
| August 14, 2019 |
Stock Option Agreement dated as of August 11, 2019 between Cell Source, Inc. and Yair Reisner Exhibit 10.41 CELL SOURCE, INC. 2019 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Cell Source, Inc. 2019 Equity Incentive Plan (the “Plan”) shall have the same defined meanings in this Stock Option Agreement (this “Option Agreement” or "Agreement"). Name: Yair Reisner Address: The undersigned Participant has been granted an Option to purcha |
|
| August 14, 2019 |
EX-10.40 2 ex10-40.htm Exhibit 10.40 CELL SOURCE, INC. 2019 EQUITY INCENTIVE PLAN This Cell Source, Inc. 2019 Equity Incentive Plan (the “Plan”) is effective as of August 13, 2019 (the “Effective Date”) 1. Purposes and Eligibility. (a) General Purpose. The purposes of this Plan are (i) to enable Cell Source, Inc., a Nevada corporation, (the “Company”) and its Affiliates to attract and retain the t |
|
| June 19, 2019 |
EX-10.39 2 ex10-39.htm Exhibit 10.39 Certain information has been excluded from this exhibit because (i) it is not material and (ii) would be competitively harmful if publicly disclosed. Veto Cell Production and Clinical Trial Program This agreement is entered into between The University of Texas M. D. Anderson Cancer Center located at 1515 Holcombe Blvd, Houston, TX 77030, USA Hereunder called MD |
|
| June 19, 2019 |
Exhibit 10.40 Certain information has been excluded from this exhibit because (i) it is not material and (ii) would be competitively harmful if publicly disclosed. SPONSORED RESEARCH AGREEMENT This Sponsored Research Agreement (“Agreement”), effective as of the 28th day of November, 2018 (the “Effective Date”) is made by and between The University of Texas M. D. Anderson Cancer Center, (“MD Anders |
|
| June 19, 2019 |
CLCS / Cell Source, Inc. 10-K/A - Annual Report - 10-K/A 1 g8724.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the years ended December 31, 2018 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55 |
|
| May 20, 2019 |
CLCS / Cell Source, Inc. 10-Q - Quarterly Report - 10-Q 1 g8702.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-5 |
|
| May 20, 2019 |
EX-10.39A 2 ex10-39a.htm EXIBIT 10.39(a) CERTAIN INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE (I) IT IS NOT MATERIAL AND (II) WOULD BE COMPETIVELY HARMFUL IF PUBLICY DISCLOSED. BRACKETS HAVE BEEN INSERTED WHERE OMITTEED INFORMATION WOULD OTHERWISE APPEAR. AMENDMENT NO. 1 TO VETO CELL PRODUCTION AND CLINICAL TRIAL PROGRAM AGREEMENT This Amendment No. 1 to the Veto Cell Production and Cli |
|
| May 15, 2019 |
CLCS / Cell Source, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 000-55413 CUSIP NUMBER 15114L104 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: March 31, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K |
|
| April 19, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2019 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-554134 32-0379665 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| April 1, 2019 |
EX-10.39 2 ex10-39.htm Exhibit 10.39 Veto Cell Production and Clinical Trial Program This agreement is entered into between The University of Texas M. D. Anderson Cancer Center located at 1515 Holcombe Blvd, Houston, TX 77030, USA Hereunder called MD Anderson and Cell Source Limited a company duly registered under the laws of the State of Israel, Company Number 514669761 having its principal place |
|
| April 1, 2019 |
CLCS / Cell Source, Inc. (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the years ended December 31, 2018 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55413 Cell Source, Inc. (Exact name of re |
|
| April 1, 2019 |
Exhibit 10.40 SPONSORED RESEARCH AGREEMENT This Sponsored Research Agreement (“Agreement”), effective as of the 28th day of November, 2018 (the “Effective Date”) is made by and between The University of Texas M. D. Anderson Cancer Center, (“MD Anderson”), a member institution of The University of Texas System (“System”), with a place of business at 1515 Holcombe Blvd., Houston, Texas, 77030, and C |
|
| November 14, 2018 |
CLCS / Cell Source, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOU |
|
| October 18, 2018 |
CLCS / Cell Source, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOURCE, |
|
| October 18, 2018 |
CLCS / Cell Source, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOURCE, |
|
| July 25, 2018 |
CLCS / Cell Source, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOU |
|
| July 25, 2018 |
Certificate of Designation with respect to Series A Preferred Stock dated November 14, 2016 Exhibit 3.5 |
|
| July 25, 2018 |
EX-10.35 5 ex10-35.htm Exhibit 10.35 THIRD AMENDMENT TO RESEARCH AND LICENCE AGREEMENT Made and entered in to this 29th day of March, 2018 By and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, “Yeda”) and CELL SOURCE LIMITED a company duly registered under the laws of Israel of 5 Kineret St |
|
| July 25, 2018 |
CLCS / Cell Source, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K ☒ ☐ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the years ended December 31, 2017 and 2016 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-55413 Cell Source, Inc. (Exact n |
|
| July 25, 2018 |
CLCS / Cell Source, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOURCE, |
|
| July 25, 2018 |
CLCS / Cell Source, Inc. 10-Q (Quarterly Report) 10-Q 1 g8597.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-5 |
|
| July 25, 2018 |
Exhibit 10.33 WARRANT NO. CBTB Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURI |
|
| July 25, 2018 |
Exhibit 10.34 SECOND AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this “Amendment”) Effective Date: November 28, 2016 By and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, “Yeda”) and CELL SOURCE LIMITED a company duly registered under the laws of Israel of 5 Kineret Street, Bnei Brak 51262 |
|
| July 25, 2018 |
EX-10.36 6 ex10-36.htm Exhibit 10.36 FOURTH AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this “Amendment”) Effective Date: March 30, 2018 By and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, “Yeda”) and CELL SOURCE LIMITED a company duly registered under the laws of Israel of 5 Kineret Str |
|
| November 18, 2016 |
Cell Source (Quarterly Report) g8331a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-554 |
|
| November 18, 2016 |
ex3-1.htm Exhibit 3.1 BARBARA K. CEGAVSKE Filed in the office of Document Number Secretary of State 20160497565-85 206 North Carson Street /s/ Barbara K. Cegavske Filing Date and Time Carson City, Nevada 89701-4299 Barbara K. Cegavske 11/14/2016 1:51 AM (775) 684-5708 Secretary of State Entity Number Website: www. nvsos.gov State of Nevada E0308832012-8 Certificate of Designation (PURSUANT TO NRS |
|
| August 15, 2016 |
Cell Source (Quarterly Report) g8280.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CEL |
|
| August 15, 2016 |
Promissory Note dated May 10, 2016 ex10-1.htm Exhibit 10.1 PROMISSORY NOTE US$53,000 May 10, 2016 All references in this Note to monies are to U.S. Dollars 1. Promise to Pay. In exchange for the sum of $53,000 (net of wire transfer fees) which CELL SOURCE INC., a Nevada Corporation (?Maker?) received from Main Street Restaurant Associates Inc. (?Holder?) on the date hereof, Maker promises to pay as set forth in this Promissory Note |
|
| May 13, 2016 |
Convertible Note due July 27, 2016 ex10-1.htm Exhibit 10.1 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?)AND APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERE |
|
| May 13, 2016 |
Cell Source (Quarterly Report) g8224.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CE |
|
| April 14, 2016 |
g8190a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2015 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 000-55413 Cell Source, Inc. (Exact nam |
|
| April 14, 2016 |
Form of Bridge Note Subscription Agreement EX-10.29 2 ex10-29.htm EXHIBIT 10.29 SUBSCRIPTION AGREEMENT Cell Source, Inc. 65 Yigal Alon Street Tel Aviv, Israel 67433 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms its agreement with Cell Source, Inc., a Nevada corporation (the “Company”), as follows: 1. This Subscription Agreement, including the Terms and Conditions For Purchase of Securities attached hereto as Annex |
|
| April 14, 2016 |
EX-10.32 5 ex10-32.htm EXHIBIT 10.32 WARRANT NO. B 150,000 Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1 |
|
| April 14, 2016 |
EXHIBIT 10.30 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)AND APPLICABLE STATE SECURITIES LAWS, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD |
|
| April 14, 2016 |
EX-10.31 4 ex10-31.htm EXHIBIT 10.31 PROMISSORY NOTE OF CELL SOURCE, INC. NOTE NO. B March 8, 2016 FOR VALUE RECEIVED, the undersigned, Cell Source, Inc. a corporation with its principal office located at 65 Yigal Alon Street, Tel Aviv Israel 67443 (the “Company” or the “Maker”), hereby unconditionally promises to pay to whose address is or the registered assignee, upon presentation of this Promis |
|
| November 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOU |
|
| November 16, 2015 |
8-K 1 g8081.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 11, 2015 CELL SOURCE, INC. (Exact Name of Registrant as Specified in Charter) Nevada 000-55413 32-0379665 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer |
|
| November 16, 2015 |
By: Name: Title: Cell Source, Inc. Exhibit 4.1 November 12, 2015 Cell Source, Inc. 65 Yigal Alon Street Tel Aviv, Israel Ladies and Gentlemen: Reference is made to the Promissory Note in the original principal amount of $ (the “Note”), dated , issued to me by Cell Source, Inc. (the “Company”). Pursuant to the Note, the Company was to pay the amounts owed under the Note on or before (the “Maturity Date”). It is hereby acknowledged a |
|
| November 16, 2015 |
ex99.htm Exhibit 99 |
|
| November 5, 2015 |
g8064.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 4, 2015 CELL SOURCE, INC. (Exact Name of Registrant as Specified in Charter) Nevada 000-55413 32-0379665 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identif |
|
| November 5, 2015 |
Inaugural Scientific Advisory Board Summit JV Pharma Collaboration Initiative ex99.htm Exhibit 99 Inaugural Scientific Advisory Board Summit JV Pharma Collaboration Initiative NEW YORK, NY November 4, 2015 - Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced their initiative for joint venture Pharma collaborations at their inaugural Scientific Advisory Board (SAB) |
|
| August 19, 2015 |
g7981.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 19, 2015 CELL SOURCE, INC. (Exact Name of Registrant as Specified in Charter) Nevada 000-55413 32-0379665 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identifi |
|
| August 19, 2015 |
Cell Source Appoints Dr. Dennis Brown as Chairman of its Board of Directors EX-99.1 2 ex99-1.htm Exhibit 99.1 Cell Source Appoints Dr. Dennis Brown as Chairman of its Board of Directors New York, NY, August 19th, 2015 - Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Dennis Brown, currently a Director of Cell Source, has been appointed Chairman |
|
| August 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOURCE, |
|
| July 28, 2015 |
ex10-2.htm Exhibit 10.2 WARRANT NO. BTB 04 100,000 Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS |
|
| July 28, 2015 |
Form of July 2015 Convertible Promissory Note EX-10.3 4 ex10-3.htm Exhibit 10.3 CONVERTIBLE PROMISSORY NOTE OF CELL SOURCE, INC. NOTE NO. CBTB[] [], 2015 FOR VALUE RECEIVED, the undersigned, Cell Source, Inc. a corporation with its principal office located at 65 Yigal Alon Street, Tel Aviv Israel 67433 (the “Company” or the “Maker”), hereby unconditionally promises to pay to [] whose address is [] or the registered assignee, upon presentation |
|
| July 28, 2015 |
g7944.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2015 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55413 32-0379665 (State or Other Jurisdiction of Incorporation) (Commission |
|
| July 28, 2015 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 PROMISSORY NOTE OF CELL SOURCE, INC. NOTE NO. BTB 04 July 20, 2015 FOR VALUE RECEIVED, the undersigned, Cell Source, Inc. a corporation with its principal office located at 65 Yigal Alon Street, Tel Aviv Israel 67433 (the “Company” or the “Maker”), hereby unconditionally promises to pay to David Zolty whose address is c/o Cell Source, 65 Yigal Alon Street, Tel Avi |
|
| July 28, 2015 |
ex10-4.htm Exhibit 10.4 WARRANT NO. BTB [] [] Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMEND |
|
| June 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2015 CELL SOURCE, INC. (Exact Name of Registrant as Specified in Charter) Nevada 000-55413 32-0379665 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| June 10, 2015 |
Cell Source Appoints Dr. Terry Strom as Chairman of Its Scientific Advisory Board Exhibit 99.1 Cell Source Appoints Dr. Terry Strom as Chairman of Its Scientific Advisory Board June 04, 2015 NEW YORK, NY - (Marketwired) - 06/04/15 - Cell Source, Inc. (OTCQB: CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, announced today that Dr. Terry Strom, Professor of Medicine and Surgery at Harvard Medical School |
|
| June 10, 2015 |
Form of Advisory/Consulting Agreement Exhibit 10.1 CONSULTING/ADVISORY AGREEMENT CONSULTING/ADVISORY AGREEMENT dated as of June 4, 2015 (the ?Agreement?) by and between Dr. Terry B. Strom, an individual (the ?Consultant?) and Cell Source, Inc., a Nevada corporation (the ?Company?). WHEREAS, the Company desires to engage Consultant to provide the services described in Schedule A (the ?Services?) and Consultant is willing to be engaged |
|
| June 3, 2015 |
Exhibit 10.1 PROMISSORY NOTE OF CELL SOURCE, INC. NOTE NO. BTB03 May 15, 2015 FOR VALUE RECEIVED, the undersigned, Cell Source, Inc. a corporation with its principal office located at 65 Yigal Alon Street, Tel Aviv Israel 67433 (the ?Company? or the ?Maker?), hereby unconditionally promises to pay to whose address is or the registered assignee, upon presentation of this Promissory Note (the ?Note? |
|
| June 3, 2015 |
Form of Note Amendment Letter Agreement EX-4.1 2 v412327ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 CELL SOURCE, INC. 65 Yigal Alon Street Tel Aviv, Israel 67433 June 1, 2015 Attn: Itamar Shimrat Mr. Shimrat: Reference is made to the Promissory Notes (the “Notes”), dated November 14, 2014 and November 26, 2014, issued to you by Cell Source, Inc. (the “Company”). Capitalized terms not otherwise defined herein shall have the meaning ascribed to the |
|
| June 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2015 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55413 32-0379665 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 3, 2015 |
Exhibit 10.2 WARRANT NO. BTB03 250,000 Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE |
|
| May 28, 2015 |
Cell Source Breakthrough Immunotherapy Technologies C orporate Overview CLCS (OTCQB) Exhibit 99.1 Cell Source Breakthrough Immunotherapy Technologies C orporate Overview CLCS (OTCQB) With the exception of historical information, the matters discussed in this presentation are forward - looking statements that involve a number of risks and uncertainties . The actual future results of Cell Source could differ significantly from those statements . Factors that could cause actual resul |
|
| May 28, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2015 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 000-55413 32-0379665 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 000-55413 CELL SOURCE, |
|
| April 1, 2015 |
Exhibit 10.2 WARRANT NO. BTB Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITI |
|
| April 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 32-0379665 (State of incorporation or organization) (I.R.S. Employer Identification No.) 65 Yigal Alon Street Tel Avi |
|
| April 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 26, 2015 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 333-187049 32-0379665 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 1, 2015 |
Form of March 2015 Promissory Note Exhibit 10.1 PROMISSORY NOTE OF CELL SOURCE, INC. NOTE NO. BTB March , 2015 FOR VALUE RECEIVED, the undersigned, Cell Source, Inc. a corporation with its principal office located at 65 Yigal Alon Street, Tel Aviv Israel 67433 (the ?Company? or the ?Maker?), hereby unconditionally promises to pay to whose address is or the registered assignee, upon presentation of this Promissory Note (the ?Note?) |
|
| March 13, 2015 |
EX-21 2 v401669ex21.htm EXHIBIT 21 EXHIBIT 21 SUBSIDIARIES Cell Source Limited, a company incorporated in Israel |
|
| March 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D. C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 333-187049 Cell Source, Inc. (Exact name of regis |
|
| December 2, 2014 |
Form of Promissory Note issued to the Company’s Chief Executive Officer Exhibit 10.1 PROMISSORY NOTE US$50,000 November 26, 2014 All references in this Note to monies are to U.S. Dollars 1. Promise to Pay. In exchange for the sum of $50,000 which CELL SOURCE INC., a Nevada Corporation (“Maker”) received from Itamar Shimrat (“Holder”) on the date hereof, Maker promises to pay as set forth in this Promissory Note (“Note”) Holder, the principal sum of $50,000 (the "Princ |
|
| December 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 26, 2014 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 333-187049 32-0379665 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-187049 CELL SO |
|
| November 12, 2014 |
CELL SOURCE, INC. 9,618,648 SHARES OF COMMON STOCK Filed pursuant to Rule 424(b)(3) Under the Securities Act of 1933, as amended Registration No. |
|
| November 7, 2014 |
CLCS / Cell Source, Inc. CORRESP - - November 7, 2014 EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| October 24, 2014 |
CLCS / Cell Source, Inc. S-1/A - - AMENDMENT TO FORM S-1 S-1/A 1 v392018s1a.htm AMENDMENT TO FORM S-1 As filed with the Securities and Exchange Commission on October 24, 2014 Registration No. 333-197972 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 2836 32-0379665 (S |
|
| October 24, 2014 |
CLCS / Cell Source, Inc. CORRESP - - October 24, 2014 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 23, 2014 |
Exhibit 10.14 BRIDGE FUNDING AGREEMENT Made and signed as of the 23rd day of October, 2013 By and Between “Cell Source", having offices at 65 Yigal Alon Street, Tel Aviv Israel (the “Company”) of the first part -And - The Investor as defined as "the Investor" in the Investment Agreement dated October 2nd, 2011, represented by Mr. David Zolty, having offices at 2727 Victoria Park Ave. Toronto, ON M |
|
| September 23, 2014 |
CLCS / Cell Source, Inc. CORRESP - - September 23, 2014 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 23, 2014 |
CLCS / Cell Source, Inc. S-1/A - - FORM S-1/A S-1/A 1 v389695s1a.htm FORM S-1/A As filed with the Securities and Exchange Commission on September 23, 2014 Registration No. 333-197972 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 2836 32-0379665 (State or j |
|
| August 19, 2014 |
Exhibit 10.11 THIRD AMENDMENT TO EVALUATION AND EXCLUSIVE OPTION AGREEMENT Made and entered in to this 15th day of August, 2014 By and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, “Yeda”) and CELL SOURCE LIMITED a company duly registered under the laws of Israel of 65 Yigal Alon St., Toyo |
|
| August 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 333-187049 CELL SOURCE, |
|
| August 15, 2014 |
CLCS / Cell Source, Inc. NT 10-Q - - NT 10-Q NT 10-Q 1 v386931nt10q.htm NT 10-Q SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 12b-25 Commission File Number: 333-187049 NOTIFICATION OF LATE FILING ¨ Form 10-K ¨ Form 11-K ¨ Form 20-F x Form 10-Q ¨ Form N-SAR For Period Ended: June 30, 2014 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 10-Q ¨ Transition Report on Form 20-F ¨ Transition Report on Form N-SAR For th |
|
| August 8, 2014 |
Form of Amendment No. 1 to Registration Rights Agreement AMENDMENT NO.1 TO REGISTRATION RIGHTS AGREEMENT This Amendment No. 1 (this “Amendment”), dated July , 2014 to the Registration Rights Agreement (“Registration Rights Agreement”), between Cell Source, Ltd. and the persons executing such Registration Rights Agreement (the “Purchasers”) is entered into by and among Cell Source, Ltd., an Israeli corporation and the Majority Holders as defined in the R |
|
| August 8, 2014 |
As filed with the Securities and Exchange Commission on August 8, 2014 As filed with the Securities and Exchange Commission on August 8, 2014 Registration No. |
|
| July 1, 2014 |
Form of Researcher Company Warrant THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT OR AN EXEMPTION FROM REGISTRATION THEREUNDER. Warrant No. CS-1 Date of Issuance: June , 2014 First Permitted Exercise Date: Second Anniversary of Date of Issuance Expiration D |
|
| July 1, 2014 |
Form of Registration Rights Agreement EX-10.2 5 v382279ex10-2.htm EXHIBIT 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of [insert], 201, (the “Effective Date”) between Cell Source, Ltd., an Israeli corporation (the “Company”), and the persons who have executed the signature page(s) hereto (each, a “Purchaser” and collectively, the “Purchasers”). RECITALS |
|
| July 1, 2014 |
EX-10.11 12 v382279ex10-11.htm EXHIBIT 10.11 |
|
| July 1, 2014 |
Cell Source Limited Introduction to Pro-forma Condensed Combined Financial Statements Cell Source Limited Introduction to Pro-forma Condensed Combined Financial Statements (Unaudited) The following unaudited pro-forma condensed combined financial statements give effect to the merger between Cell Source Limited (“Cell Source”) and Ticket to See, Inc. |
|
| July 1, 2014 |
WARRANT NO. Shares WARRANT TO PURCHASE COMMON STOCK VOID AFTER 5:30 P.M., EASTERN TIME, ON THE EXPIRATION DATE THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, AC |
|
| July 1, 2014 |
Consulting Agreement by and between Cell Source Limited and Professor Yair Reisner EX-10.12 13 v382279ex10-12.htm EXHIBIT 10.12 |
|
| July 1, 2014 |
Form of Subscription Agreement EX-10.1 4 v382279ex10-1.htm EXHIBIT 10.1 SUBSCRIPTION AGREEMENT Cell Source, Ltd. 65 Yigal Alon Street, 23rd Floor Tel Aviv 67433, Israel Ladies and Gentlemen: 1. Subscription. The undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from Cell Source, Ltd. (the “Company” or “Cell Source”) the number of units (the “Units”) set forth on the signature pa |
|
| July 1, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2014 CELL SOURCE, INC. (Exact name of registrant as specified in its charter) Nevada 333-187049 32-0379665 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| July 1, 2014 |
CELL SOURCE, LTD. WARRANT TO PURCHASE ORDINARY EX-10.3 6 v382279ex10-3.htm EXHIBIT 10.3 Warrant Certificate No. NEITHER THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, ASSIGNED OR OTHERWISE TRANSFERRED |
|
| July 1, 2014 | ||
| July 1, 2014 | ||
| July 1, 2014 |
SHARE EXCHANGE AGREEMENT This Share Exchange Agreement (the “Agreement”), is made and entered into as of June 30, 2014, by and among Ticket to See, Inc. |
|
| July 1, 2014 |
Cell Source Inc. Announces Acquisition and $3.6 Million Private Placement to Advance Novel Cancer Therapies TEL AVIV, ISRAEL and NEW YORK, USA (Marketwire – July 1, 2014) Cell Source, Inc. (OTCQB: CLCS) ("Cell Source") today announced the successful acquisition (the “Acquisition”), through a share exchange agreement, of all of the outstanding shares of Cell Source (Israel) Ltd., a pre-clinical cel |
|
| July 1, 2014 |
Amendment to Research and License Agreement EX-10.8 10 v382279ex10-8.htm EXHIBIT 10.8 |
|
| July 1, 2014 |
The Companies Law Articles of association of the Company 1. Name of the Company The proposed name of the Company: Cell Source Ltd. 2. The aims of the Company 2.1 Pursuant to section 32(1) of the Law – to engage in any lawful occupation. 2.2 To pursue the completion of research, development, and trading of technologies related to cell therapy and the use of fetal cells for growing tissue for the pu |
|
| July 1, 2014 |
June 30, 2014 Securities and Exchange Commission Washington, DC 20549 Ladies and Gentlemen: We have read Item 4.01 of Form 8-K of Cell Source, Inc. dated June 30, 2014. We agree with the statements made concerning our firm contained therein. Yours very truly, /s/ Paritz & Company, P.A. Paritz & Company, P.A. |
